Vasileva I A, Ostroumova M N, Dilman V M
Neoplasma. 1982;29(4):469-75.
The study included 191 patients with obesity, atherosclerosis, diabetes mellitus, endometrial cancer, breast cancer and healthy subjects of various age. Somatomedin activity was determined by incorporation of radioactive natrium sulfate in vitro into the cartilage of female rats. The results of the study showed that somatomedin activity was not changed in subjects with normal metabolic parameters and ranged from 0.47 to 0.69 U/ml. In patients with diabetes mellitus, atherosclerosis and obesity accompanied by increased blood concentration of cholesterol and triglycerides, somatomedin activity rose up to 1.36- 1.62 U/ml. In patients with breast and endometrial cancer somatomedin activity was also increased, particularly in those with hypercholesterolemia and hypertriglyceridemia (3.04 U/ml for breast cancer patients and 2.20 U/ml for endometrial cancer patients). Theoretically, this may promote proliferation of somatic cells and thus contribute to tumor processes in oncological patients whose pool of cells is extremely sensitive to mitogenic agents.
该研究纳入了191名患有肥胖症、动脉粥样硬化、糖尿病、子宫内膜癌、乳腺癌的患者以及不同年龄段的健康受试者。通过体外将放射性硫酸钠掺入雌性大鼠软骨中来测定生长调节素活性。研究结果表明,代谢参数正常的受试者生长调节素活性未发生变化,范围为0.47至0.69 U/ml。在伴有胆固醇和甘油三酯血液浓度升高的糖尿病、动脉粥样硬化和肥胖症患者中,生长调节素活性升至1.36 - 1.62 U/ml。在乳腺癌和子宫内膜癌患者中,生长调节素活性也有所增加,尤其是在那些患有高胆固醇血症和高甘油三酯血症的患者中(乳腺癌患者为3.04 U/ml,子宫内膜癌患者为2.20 U/ml)。从理论上讲,这可能会促进体细胞增殖,从而在细胞池对有丝分裂剂极其敏感的肿瘤患者中导致肿瘤进展。